NasdaqGS - Nasdaq Real Time Price ? USD
ACADIA Pharmaceuticals Inc. (ACAD)
At close: September 9 at 4:00 PM EDT
After hours: September 9 at 7:07 PM EDT
Research Analysis
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 17 | 18 | 16 | 17 |
| Avg. Estimate | 0.14 | 0.09 | 0.52 | 0.83 |
| Low Estimate | 0.07 | -0.15 | 0.31 | 0.2 |
| High Estimate | 0.22 | 0.23 | 0.75 | 1.48 |
| Year Ago EPS | -0.4 | 0.28 | -0.37 | 0.52 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 17 | 17 | 19 | 19 |
| Avg. Estimate | 248.67M | 255.6M | 952.11M | 1.06B |
| Low Estimate | 236M | 241.57M | 928.96M | 1B |
| High Estimate | 255M | 262.9M | 964M | 1.14B |
| Year Ago Sales | 211.7M | 231.04M | 726.44M | 952.11M |
| Sales Growth (year/est) | 17.50% | 10.60% | 31.10% | 11.40% |
Earnings History
| CURRENCY IN USD | 9/30/2023 | 12/31/2023 | 3/31/2024 | 6/30/2024 |
|---|---|---|---|---|
| EPS Est. | -0.43 | 0.3 | 0.05 | 0.18 |
| EPS Actual | -0.4 | 0.28 | 0.1 | 0.2 |
| Difference | 0.03 | -0.02 | 0.05 | 0.02 |
| Surprise % | 7.00% | -6.70% | 100.00% | 11.10% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 0.14 | 0.09 | 0.52 | 0.83 |
| 7 Days Ago | 0.14 | 0.09 | 0.52 | 0.83 |
| 30 Days Ago | 0.14 | 0.1 | 0.54 | 0.89 |
| 60 Days Ago | 0.18 | 0.13 | 0.59 | 1.14 |
| 90 Days Ago | 0.18 | 0.13 | 0.58 | 1.13 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | ACAD | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 135.00% | -- | -- | 7.00% |
| Next Qtr. | -67.90% | -- | -- | 11.10% |
| Current Year | 240.50% | -- | -- | 4.10% |
| Next Year | 59.60% | -- | -- | 13.00% |
| Next 5 Years (per annum) | -357.00% | -- | -- | 11.94% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Upgrades & Downgrades
| Maintains | Citigroup: Buy to Buy | 8/8/2024 |
| Maintains | UBS: Buy to Buy | 8/8/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 8/8/2024 |
| Maintains | Needham: Buy to Buy | 8/7/2024 |
| Maintains | Cantor Fitzgerald: Overweight to Overweight | 8/7/2024 |
| Maintains | RBC Capital: Outperform to Outperform | 8/7/2024 |
Related Tickers
INCY Incyte Corporation
62.26
+1.63%
FOLD Amicus Therapeutics, Inc.
11.51
-1.20%
BCRX BioCryst Pharmaceuticals, Inc.
7.67
-3.88%
SLNO Soleno Therapeutics, Inc.
48.75
+0.43%
EXEL Exelixis, Inc.
25.51
+1.43%
DNLI Denali Therapeutics Inc.
25.59
+1.35%
BMRN BioMarin Pharmaceutical Inc.
84.33
+0.30%
BPMC Blueprint Medicines Corporation
86.55
+0.14%
ARWR Arrowhead Pharmaceuticals, Inc.
21.76
-2.07%
IMVT Immunovant, Inc.
31.44
-7.61%